EBS vs LFCR
EBS: Emergent BioSolutions is a specialized biopharmaceutical firm that provides critical medical countermeasures and manufacturing services to protect against global public health threats and opioid overdose emergencies. LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry.
Side-by-side fundamentals
| Metric | EBS | LFCR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.33 | $4.34 | |
| Market cap as of 2026-07-31 | $384M | $161M | |
| P/E as of 2026-07-31 | 7.30 | n/a | |
| Net margin as of 2026-07-31 | -1.3% | -26.5% | EBS higher |
| Gross margin as of 2026-07-31 | +54.3% | +30.0% | EBS higher |
| Operating margin as of 2026-07-31 | +9.0% | -1.9% | EBS higher |
| ROE as of 2026-07-31 | -1.6% | -126.8% | EBS higher |
| ROA as of 2026-07-31 | -0.6% | -18.9% | EBS higher |
| Debt / equity as of 2026-07-31 | 1.10 | 7.16 | EBS lower |
| Revenue growth (YoY) as of 2026-07-31 | -29.9% | +27.6% | LFCR higher |
| Revenue CAGR (3y) SEC XBRL | -12.7% | +5.3% | LFCR higher |
| Beta as of 2026-07-31 | 2.41 | 1.15 | |
| 1-year return as of 2026-07-27 close | +2.2% | -41.6% | EBS higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.